Cancer and thrombosis: Recent advances

Current Oncology

Volumn 15, Issue 6, 2008, Pages 48-49

  Solymoss, Susan S ^a  

^a MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Epidemiology; Low molecular weight heparin; Risk factors; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN;

CANCER PATIENT; CARDIOVASCULAR RISK; CLINICAL PROTOCOL; DISEASE ASSOCIATION; HUMAN; NEOPLASM; PATIENT CARE; REVIEW; THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM;

EID: 68749105918     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: 10.3747/co.v15i6.296     Document Type: Review

References (13)

1. Trousseau A. Phlegmasia alba dolens. Clinique Medicale l'Hotel-Dieu de Paris. Vol. 3. London: New Sydenham Society; 1865: 695-727.
2. Buller HR, van Doormaal FF, van Sluis GL, Kamphuisen PW. Cancer and thrombosis: From molecular mechanisms to clinical presentations. J Thromb Haemost 2007;5(suppl 1):246-54.
3. Levitan N, Dowlati A, Remick SC, et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims data. Medicine (Baltimore) 1999;78:285-91.
4. Khorana AA, Francis CW, Culakova E, Kuderer NM, Lyman GH. Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients. Cancer 2007;110:2339-46.
5. Haddad TC, Greeno EW. Chemotherapy-induced thrombosis. Thromb Res 2006;118:555-68.
6. Zangari M, Barlogie B, Anaissie E, et al. Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: Effects of prophylactic and therapeutic anticoagulation. Br J Haematol 2004;126:715-21.
7. Prandoni P, Lensing AW, Piccioli A, et al Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-8.
8. Lee AY, Levine MN, Baker RI, et al. on behalf of the CLOT investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003;349:146-53.
9. Hull RD, Pineo GF, Brant RF, et al. on behalf of the LITE Trial investigators. Long-term low-molecular-weight heparin versus usual care in proximal-vein thrombosis patients with cancer. Am J Med 2006;119:1062-72.
10. Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000;343:1846-50.
11. Kuderer NM, Khorana AA, Lyman GH, Francis CW. A metaanalysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: Impact on survival and bleeding complications. Cancer 2007;110:1149-60.
12. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007;25:5490-505.
13. Brose KMJ, Lee AYY. Cancer-associated thrombosis: Prevention and treatment. Curr Oncol 2008;15(suppl 1):S58-67.